Blood Volume News
-
Daxor Corporation Announces Significant Expansion With Five Hospitals Implementing Its BVA-100 Blood Volume Diagnostic for Heart Failure Patients
Daxor Corporation (NASDAQ: DXR), the global leader in blood volume measurement technology, today announces five new hospitals have implemented the Company’s BVA-100 blood volume diagnostic for clinical use to guide fluid management in heart failure patients during the first quarter of 2023. The addition of these hospitals contributes to the significant growth of blood volume analysis (BVA) ...
-
Pilot Randomized Controlled Trial Validates Daxor BVA-100® Diagnostic for Heart Failure Patients
Oak Ridge, TN – March 23, 2023 — Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, today announces new pilot randomized control trial (RCT) data from Duke Heart validating the greater accuracy of the Company’s BVA-100 diagnostic in optimizing decongestion therapy for heart failure patients and pointed to a strong signal toward reducing ...
-
New Study Confirms Daxor’s BVA-100® Volume Metric Compared to CardioMEMS® Pressure Metric Has Unique Clinical Utility as a Diagnostic for Heart Failure Patients
Oak Ridge, TN – March 23, 2023 — Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, today announces new data validating the benefits of the Company’s BVA-100 diagnostic in optimizing individualized therapy for heart failure patients. Data were presented at the Technology Heart Failure Therapeutics Conference, which focuses on device and ...
-
New Study Confirms Daxor’s BVA-100 Volume Metric Compared to CardioMEMS Pressure Metric Has Unique Clinical Utility as a Diagnostic for Heart Failure Patients
Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, today announces new data validating the benefits of the Company’s BVA-100 diagnostic in optimizing individualized therapy for heart failure patients. Data were presented at the Technology Heart Failure Therapeutics Conference, which focuses on device and technology-based treatments in heart failure. ...
-
Pilot Randomized Controlled Trial Validates Daxor BVA-100 Diagnostic for Heart Failure Patients
Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, today announces new pilot randomized control trial (RCT) data from Duke Heart validating the greater accuracy of the Company’s BVA-100 diagnostic in optimizing decongestion therapy for heart failure patients and pointed to a strong signal toward reducing hospital length of stay in a pilot cohort of 31 ...
-
Daxor Corporation Appoints Linda Cooper, Vice President Project Management
Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces the appointment of Linda Cooper as Vice President of Project Management. “Linda joins Daxor with over 30 years of experience in product development and commercialization in the medical device industry. Linda’s proven track record makes her an excellent addition to the Daxor team ...
-
Daxor Corporation Joins the Heart Failure Society of America (HFSA) as a Corporate Member
Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces joining the Heart Failure Society of America (HFSA) as a corporate member to collaborate and deepen engagement with leaders in the field of heart failure. “The HFSA is the premier society focused on improving Heart Failure outcomes, a condition that more than 6 million Americans ...
-
Newly Published Study Proves Value and CliNewly Published Study Proves Value and Clinical Benefit of Daxor’s Blood Volume (BVA-100) Diagnostic in the Evaluationnical Benefit of Daxor’s Blood Volume (BVA-100) Diagnostic in the Evaluation of Heart Failure
Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces a new study in the Journal of Cardiovascular Translational Research that examined pressure-volume profiles in heart failure patients using Daxor’s BVA-100 blood test to measure intravascular volume overload compared to a commercially available implantable pulmonary artery diastolic ...
-
Daxor Corporation Announces Closing of $2.1 million Underwritten Public Offering and Exercise of Over-Allotment Option
DAXOR CORPORATION (Nasdaq: DXR) (“Daxor”, or the “Company”), the global leader in blood volume measurement technology, today announced the closing of its previously announced underwritten public offering consisting of 210,527 shares of its common stock at a public offering price of $9.50 per share. In addition, the underwriter has partially exercised its over-allotment ...
-
Daxor Corporation Announces Pricing of $2.0 million Underwritten Public Offering
DAXOR CORPORATION (Nasdaq: DXR) (“Daxor”, or the “Company”), the global leader in blood volume measurement technology, today announced the pricing of an underwritten public offering consisting of 210,527 shares of its common stock at a public offering price of $9.50 per share. The gross proceeds to Daxor from the offering, before deducting the underwriting commissions and ...
-
Daxor Corporation Announces Launch of Proposed Underwritten Public Offering
DAXOR CORPORATION (Nasdaq: DXR) (“Daxor”, or the “Company”), the global leader in blood volume measurement technology, today announced that it has commenced an underwritten public offering of shares of its common stock. All of the shares of common stock are being offered by Daxor. In addition, Daxor intends to grant the underwriter in the offering a 45-day option to ...
-
Live Webinar by MedAxiom Features Best Practices Using Daxor’s Blood Volume Analysis (BVA-100) to Improve Heart Failure Outcomes & Reduce Costs
Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces Daxor’s BVA-100 diagnostic will be featured in a MedAxiom Academy webinar – Best Practices for Using Blood Volume Analysis to Reduce Heart Failure LOS, Readmissions, Mortality and Costs on November 17, 2022, at 1pm ET. This live webinar will take a deep dive into the best ...
-
Newly Published Study Demonstrates Significant Clinical Utility of Daxor’s Blood Volume (BVA-100) Diagnostic in the Evaluation of Heart Failure
Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces a new study in the prestigious Journal of Cardiac Failure demonstrating the importance and clinical utility of Daxor’s BVA-100 blood test in heart failure (HF). The researchers showed that Daxor’s BVA-100 was able to measure intravascular volume overload in heart failure ...
-
Daxor Corporation to Exhibit at American Heart Association’s Scientific Sessions 2022
Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces it will be attending the American Heart Association Scientific Sessions (AHA) at McCormick Place Convention Center in Chicago, IL from November 5-7th, 2022. “The AHA Scientific Sessions is a leading event connecting over 15,000 experts from over one hundred countries focused on ...
-
ISET technology applied to DLA products from NSCLC patients identified more CTC than other systems
We are enthusiastic to share the results of the research conducted by Dr Tamminga from the University of Groningen. ISET Technology applied to DLA products. This research opens a new interesting way to look at the very rare cancer cells in the patient bloodstream. Rarecells Diagnostics (France), a leading liquid biopsy company, is pleased to announce that the University Medical Center of ...
-
Daxor Corporation to Exhibit & Present at the Medaxiom Cardiovascular Transforum Conference Fall’22 to Advance Awareness & Further Adoption of Daxor’s Blood Volume Diagnostic (BVA-100)
The Premier Event for The Cardiovascular Industry’s Leading Network of Executives and Clinicians – Sharing Best Practices, Guidance and Resources to Dramatically Improve Their Business and Patient-Care Outcomes Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces today it will be exhibiting for the first time at the MedAxiom CV ...
-
Expert Panel Calls for Use of Blood Volume Measurement to Assess Heart Failure Patients at Key Scientific Meeting
Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces that a scientific session titled “Debating Volume-based versus Pressure-based Methods and Devices to Measure Congestion in Heart Failure” was held during the Heart Failure Society of America Annual Scientific Meeting on October 3rd, 2022, in Washington, DC. In a debate format ...
-
Study Data from Mayo Clinic on Heart Failure Treatment Effectiveness Utilizing Daxor BVA-100 Presented at Key Scientific Meeting
Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, today announces new data from the Mayo Clinic in Rochester, NY validating the benefits of the Company’s BVA-100 blood test for patients with heart failure. Data were presented at the Heart Failure Society of America (HFSA) Annual Scientific Meeting – which brought together the world’s ...
-
New Data Shows 85% Reduction in One-Year Mortality for Medicare Heart Failure Patients With BVA-Guided Care
Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, today announces new data validating the benefits of the Company’s BVA-100 blood test for heart failure patients. Data were presented at the Heart Failure Society of America (HFSA) Annual Scientific Meeting (ASM) 2022 – which brought together the world’s leading experts in heart failure from ...
-
New Studies Validating the Uniqueness of the BVA-100 Blood Test for Heart Failure Patients Compared to Pressure Measures
Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, today announces new data from Duke Heart validating the benefits of the Company’s BVA-100 blood test in optimizing individualized therapy for heart failure patients. Data were presented at the Heart Failure Society of America (HFSA) Annual Scientific Meeting (ASM) 2022 – which brought together ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you